The DOI matches its Crossref record.
Heterozygous Arg753Gln Polymorphism of Human TLR-2 Impairs Immune Activation by Borrelia burgdorferi and Protects from Late Stage Lyme Disease
Open accessAbstract
Lyme disease (LD) is caused by Borrelia burgdorferi and displays different stages, including localized, early disseminated, and persistent infection, all of which are associated with profound inflammatory reactions in the host. Induction of proinflammatory cytokines by B. burgdorferi is mainly mediated by outer surface proteins interacting with TLR-2/TLR-1 heterodimers. In this study, we show that TNF-α induction by Borrelia lysate was impaired in heterozygous TLR-2 knockout mice, while reactivity to lipoteichoic acid, another TLR-2 ligand signaling via TLR-2/TLR-6 heterodimers, was unaffected. Blood from individuals heterozygous for the TLR-2 polymorphism Arg753Gln was tested for cytokine release upon stimulation with Borrelia lysate, and induction of TNF-α and IFN-γ was significantly lower as compared with individuals not exhibiting this variation. Overexpression of TLR-2 carrying the Arg753Gln polymorphism in HEK 293 cells led to a significantly stronger impairment of activation by TLR-2/TLR-1 ligands as compared with TLR-2/TLR-6 ligands. To study whether heterozygosity for the Arg753Gln variant of TLR-2 influenced susceptibility for LD, we analyzed 155 patients for this polymorphism. The Arg753Gln variant occurs at a significantly lower frequency in LD patients as compared with matched controls (5.8 vs 13.5%, odds ratio 0.393, 95% confidence interval 0.17–0.89, p = 0.033), with an even more pronounced difference when late stage disease was observed (2.3 vs 12.5%, odds ratio 0.163, 95% confidence interval 0.04–0.76, p = 0.018). These data suggest that Arg753Gln may protect from the development of late stage LD due to a reduced signaling via TLR-2/TLR-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Casanova, J.-L., Abel, L., & Quintana-Murci, L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101335 · Cited by 366
Johnson, C. M., Lyle, E. A., Omueti, K. O., Stepensky, V. A., Yegin, O., Alpsoy, E., Hamann, L., Schumann, R. R., & Tapping, R. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7520 · Cited by 264
Self-citationToll-like receptor polymorphisms and susceptibility to human disease
Misch, E. A., & Hawn, T. R. (2008) · Clinical Science · doi:10.1042/cs20070214 · Cited by 263
Toll-like Receptors in Defense and Damage of the Central Nervous System
Aravalli, R. N., Peterson, P. K., & Lokensgard, J. R. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9071-5 · Cited by 173
“The Arg753Gln polymorphism, originally described in patients with leprosy (Kang and Chae 2001) also confers susceptibility to tuberculosis (Ogus et al. 2004; Schroder et al. 2005).”
BackgroundPlantinga, T. S., Hamza, O. J. M., Willment, J. A., Ferwerda, B., van de Geer, N. M. D., Verweij, P. E., Matee, M. I. N., Banahan, K., O'Neill, L. A. J., Kullberg, B.-J., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181e53c64 · Cited by 53
Metadata
- Authors
- Schröder, N. W. J., Diterich, I., Zinke, A., Eckert, J., Draing, C., Baehr, V. V., Hassler, D., Priem, S., Hahn, K., Michelsen, K. S., Hartung, T., Burmester, G. R., Göbel, U. B., Hermann, C., & Schumann, R. R.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08
- Volume
- 175
- Issue
- 4
- Pages
- 2534-2540
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2096743939
- Cited by
- 192
- References
- 0
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.